Your browser doesn't support javascript.
loading
Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
Sokolenko, Anna P; Bakaeva, Elvina Kh; Venina, Aigul R; Kuligina, Ekaterina Sh; Romanko, Alexandr A; Aleksakhina, Svetlana N; Belysheva, Yana V; Belogubova, Evgeniya V; Stepanov, Ilya A; Zaitseva, Olga A; Yatsuk, Olga S; Togo, Alexandr V; Khamgokov, Zaur M; Kadyrova, Azinat O; Pirmagomedov, Albert Sh; Bolieva, Marina B; Epkhiev, Alexandr A; Tsutsaev, Aslan K; Chakhieva, Madina D; Khabrieva, Khalimat M; Khabriev, Idris M; Murachuev, Mirza A; Buttaeva, Bella N; Baboshkina, Liliya S; Bayramkulova, Fatima I; Katchiev, Islam R; Alieva, Lina Kh; Raskin, Grigory A; Orlov, Sergey V; Khachmamuk, Zarema K; Levonyan, Karine R; Gichko, Dariya M; Kirtbaya, Dmitriy V; Degtyariov, Alexey M; Sultanova, Luisa V; Musayeva, Hedi S; Belyaev, Alexey M; Imyanitov, Evgeny N.
Afiliação
  • Sokolenko AP; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758. annasokolenko@mail.ru.
  • Bakaeva EK; St. Petersburg Pediatric Medical University, St. Petersburg, Russia. annasokolenko@mail.ru.
  • Venina AR; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Kuligina ES; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Romanko AA; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Aleksakhina SN; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Belysheva YV; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Belogubova EV; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Stepanov IA; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Zaitseva OA; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Yatsuk OS; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Togo AV; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Khamgokov ZM; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Kadyrova AO; Republican Cancer Center, The Kabardino-Balkarian Republic, Nalchik, Russia.
  • Pirmagomedov AS; Republican Cancer Center, The Kabardino-Balkarian Republic, Nalchik, Russia.
  • Bolieva MB; City Hospital No.1, The Kabardino-Balkarian Republic, Nalchik, Russia.
  • Epkhiev AA; Republican Cancer Center, The Republic of North Ossetia-Alania, Vladikavkaz, Russia.
  • Tsutsaev AK; Republican Cancer Center, The Republic of North Ossetia-Alania, Vladikavkaz, Russia.
  • Chakhieva MD; Republican Cancer Center, The Republic of North Ossetia-Alania, Vladikavkaz, Russia.
  • Khabrieva KM; Republican Cancer Center, The Republic of Ingushetia, Pliyevo, Russia.
  • Khabriev IM; Republican Cancer Center, The Republic of Ingushetia, Pliyevo, Russia.
  • Murachuev MA; Republican Cancer Center, The Republic of Ingushetia, Pliyevo, Russia.
  • Buttaeva BN; Republican Cancer Center, The Republic of Dagestan, Makhachkala, Russia.
  • Baboshkina LS; Republican Bureau of Pathology, The Republic of Dagestan, Makhachkala, Russia.
  • Bayramkulova FI; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
  • Katchiev IR; Republican Cancer Center, The Karachay-Cherkess Republic, Cherkessk, Russia.
  • Alieva LK; Republican Cancer Center, The Karachay-Cherkess Republic, Cherkessk, Russia.
  • Raskin GA; Republican Cancer Center, The Karachay-Cherkess Republic, Cherkessk, Russia.
  • Orlov SV; Dr. Sergey Berezin Medical Institute of Biological Systems, St. Petersburg, Russia.
  • Khachmamuk ZK; I.P. Pavlov St.-Petersburg State Medical University, St. Petersburg, Russia.
  • Levonyan KR; Regional Clinical Cancer Center, Krasnodar, Russia.
  • Gichko DM; Regional Clinical Cancer Center, Krasnodar, Russia.
  • Kirtbaya DV; City Cancer Center, Sochi, Russia.
  • Degtyariov AM; City Cancer Center, Sochi, Russia.
  • Sultanova LV; City Cancer Center, Sochi, Russia.
  • Musayeva HS; Republican Cancer Center, Grozny, The Chechen Republic, Russia.
  • Belyaev AM; Republican Cancer Center, Grozny, The Chechen Republic, Russia.
  • Imyanitov EN; Department of Tumor Growth Biology, N.N. Petrov Institute of Oncology, Leningradskaya, 68, Pesochny-2, St. Petersburg, Russia, 197758.
Breast Cancer Res Treat ; 203(2): 307-315, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37851290
ABSTRACT

BACKGROUND:

Mountain areas of the North Caucasus host several large ethnic communities that have preserved their national identity over the centuries.

METHODS:

This study involved high-grade serous ovarian cancer (HGSOC) and breast cancer (BC) patients from Dagestan (HGSOC 37; BC 198), Kabardino-Balkaria (HGSOC 68; BC 155), North Ossetia (HGSOC 51; BC 104), Chechnya (HGSOC 68; BC 79), Ingushetia (HGSOC 19; BC 103), Karachay-Cherkessia (HGSOC 13; BC 47), and several Armenian settlements (HGSOC 16; BC 101). The group of BC patients was enriched by young-onset and/or family history-positive and/or bilateral and/or receptor triple-negative cases. The entire coding region of BRCA1, BRCA2, PALB2, and ATM genes was analyzed by next-generation sequencing.

RESULTS:

A significant contribution of BRCA1/2 pathogenic variants (PVs) to HGSOC and BC development was observed across all North Caucasus regions (HGSOC 19-39%; BC 6-13%). Founder alleles were identified in all ethnic groups studied, e.g., BRCA1 c.3629_3630delAG in Chechens, BRCA2 c.6341delC in North Ossetians, BRCA2 c.5351dupA in Ingush, and BRCA1 c.2907_2910delTAAA in Karachays. Some BRCA1/2 alleles, particularly BRCA2 c.9895C > T, were shared by several nationalities. ATM PVs were detected in 14 patients, with c.1673delG and c.8876_8879delACTG alleles occurring twice each. PALB2 heterozygosity was observed in 5 subjects, with one variant seen in 2 unrelated women.

CONCLUSION:

This study adds to the evidence for the global-wide contribution of BRCA1/2 genes to HGSOC and BC morbidity, although the spectrum of their PVs is a subject of ethnicity-specific variations. The data on founder BRCA1/2 alleles may be considered when adjusting the BRCA1/2 testing procedure to the ethnic origin of patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Proteínas Mutadas de Ataxia Telangiectasia / População do Leste Europeu Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias da Mama / Proteínas Mutadas de Ataxia Telangiectasia / População do Leste Europeu Limite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Ano de publicação: 2024 Tipo de documento: Article